U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H9AsNO5.Na
Molecular Weight 297.0721
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACETARSOL SODIUM

SMILES

[Na+].CC(=O)NC1=CC(=CC=C1O)[As](O)([O-])=O

InChI

InChIKey=UYQUMYMLNDDPIP-UHFFFAOYSA-M
InChI=1S/C8H10AsNO5.Na/c1-5(11)10-7-4-6(9(13,14)15)2-3-8(7)12;/h2-4,12H,1H3,(H,10,11)(H2,13,14,15);/q;+1/p-1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://jama.jamanetwork.com/article.aspx?articleid=264264

Acetarsone is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties. It was first discovered in 1921 at Pasteur Institute by Ernest Fourneau, and sold under the brand name Stovarsol (fourneau is the French word for stove). Before stovarsol was used in the treatment of congenital syphilis, it had already been used in other diseases : amoebiasis, acquired syphilis, yaws, trypanosomiasis and malaria, and a formidable list of toxic manifestations can be compiled from the literature. Bender (I927) recorded six cases of poisoning with malaise, fever, cedema, jaundice, diarrhoea, albuminuria, bronchitis, coryza and skin troubles, such as diffuse erythema, dryness and pruritus. Of 232 cases of amoebiasis treated by Brown (I935) without a death, thirteen (5.6%) had toxic erythemata, some of them so severe as to amount to exfoliative dermatitis. Although its mechanism of action is not fully known, acetarsone may bind to protein-containing sulfhydryl groups located in the parasite, thereby forming lethal As-S bonds. This may prevent their functioning and eventually kill the parasite.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
220 mg 2 times / day steady-state, vaginal
Recommended
Dose: 220 mg, 2 times / day
Route: vaginal
Route: steady-state
Dose: 220 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Disc. AE: abdominal pain, vomiting...
Other AEs: confused...
AEs leading to
discontinuation/dose reduction:
abdominal pain (1 pt)
vomiting (1 pt)
rash (1 pt)
Other AEs:
confused (1 pt)
Sources:
250 mg 1 times / day multiple, vaginal
Recommended
Dose: 250 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Disc. AE: Exfoliative dermatitis...
AEs leading to
discontinuation/dose reduction:
Exfoliative dermatitis (1 pt)
Sources:
500 mg 1 times / day steady-state, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady-state
Dose: 500 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
Disc. AE: Stevens-Johnson syndrome...
AEs leading to
discontinuation/dose reduction:
Stevens-Johnson syndrome (1 pt)
Sources:
250 mg 2 times / day steady-state, oral
Studied dose
Dose: 250 mg, 2 times / day
Route: oral
Route: steady-state
Dose: 250 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Other AEs: thrombocytosis...
Other AEs:
thrombocytosis (1 pt)
Sources:
AEs

AEs

AESignificanceDosePopulation
confused 1 pt
220 mg 2 times / day steady-state, vaginal
Recommended
Dose: 220 mg, 2 times / day
Route: vaginal
Route: steady-state
Dose: 220 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
abdominal pain 1 pt
Disc. AE
220 mg 2 times / day steady-state, vaginal
Recommended
Dose: 220 mg, 2 times / day
Route: vaginal
Route: steady-state
Dose: 220 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
rash 1 pt
Disc. AE
220 mg 2 times / day steady-state, vaginal
Recommended
Dose: 220 mg, 2 times / day
Route: vaginal
Route: steady-state
Dose: 220 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
vomiting 1 pt
Disc. AE
220 mg 2 times / day steady-state, vaginal
Recommended
Dose: 220 mg, 2 times / day
Route: vaginal
Route: steady-state
Dose: 220 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Exfoliative dermatitis 1 pt
Disc. AE
250 mg 1 times / day multiple, vaginal
Recommended
Dose: 250 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Stevens-Johnson syndrome 1 pt
Disc. AE
500 mg 1 times / day steady-state, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady-state
Dose: 500 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
thrombocytosis 1 pt
250 mg 2 times / day steady-state, oral
Studied dose
Dose: 250 mg, 2 times / day
Route: oral
Route: steady-state
Dose: 250 mg, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Stovarsol in the Treatment of Congenital and Acquired Syphilis.
1941-01
THE ARSENO-THERAPY OF SYPHILIS; STOVARSOL, AND TRYPARSAMIDE.
1925-10
Patents

Patents

Sample Use Guides

one to four grains
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
ACETARSOL, MONOSODIUM SALT
Preferred Name English
ACETARSOL SODIUM
WHO-DD  
Common Name English
Acetarsol sodium [WHO-DD]
Common Name English
ACETARSONE SODIUM
Common Name English
SODIUM N-ACETYL-4-HYDROXY-M-ARSANILATE
Common Name English
SODIUM ACETARSONE
Common Name English
Code System Code Type Description
CAS
5892-48-8
Created by admin on Mon Mar 31 18:41:44 GMT 2025 , Edited by admin on Mon Mar 31 18:41:44 GMT 2025
PRIMARY
ECHA (EC/EINECS)
227-573-1
Created by admin on Mon Mar 31 18:41:44 GMT 2025 , Edited by admin on Mon Mar 31 18:41:44 GMT 2025
ALTERNATIVE
FDA UNII
JS0786858H
Created by admin on Mon Mar 31 18:41:44 GMT 2025 , Edited by admin on Mon Mar 31 18:41:44 GMT 2025
PRIMARY
PUBCHEM
23668632
Created by admin on Mon Mar 31 18:41:44 GMT 2025 , Edited by admin on Mon Mar 31 18:41:44 GMT 2025
PRIMARY
EVMPD
SUB00250MIG
Created by admin on Mon Mar 31 18:41:44 GMT 2025 , Edited by admin on Mon Mar 31 18:41:44 GMT 2025
PRIMARY
SMS_ID
100000078826
Created by admin on Mon Mar 31 18:41:44 GMT 2025 , Edited by admin on Mon Mar 31 18:41:44 GMT 2025
PRIMARY
MESH
C005284
Created by admin on Mon Mar 31 18:41:44 GMT 2025 , Edited by admin on Mon Mar 31 18:41:44 GMT 2025
PRIMARY
CAS
55588-51-7
Created by admin on Mon Mar 31 18:41:44 GMT 2025 , Edited by admin on Mon Mar 31 18:41:44 GMT 2025
NON-SPECIFIC STOICHIOMETRY
ECHA (EC/EINECS)
259-714-8
Created by admin on Mon Mar 31 18:41:44 GMT 2025 , Edited by admin on Mon Mar 31 18:41:44 GMT 2025
PRIMARY
EPA CompTox
DTXSID601080839
Created by admin on Mon Mar 31 18:41:44 GMT 2025 , Edited by admin on Mon Mar 31 18:41:44 GMT 2025
PRIMARY